United States securities and exchange commission logo

                          December 7, 2020

       Mel Sorensen
       Chief Executive Officer
       Galera Therapeutics, Inc.
       2 W Liberty Blvd #100
       Malvern, PA 19355

                                                        Re: Galera
Therapeutics, Inc.
Statement on Form S-3
                                                            Filed December 1,
                                                            File No. 333-251061

       Dear Mr. Sorensen:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Margaret
Schwartz at 202-551-7153 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Nathan Ajiashvili, Esq.